Study summary
Tiragolumab plus atezolizumab after chemoradiation missed its goal
31% lowerrisk of death with atezolizumab alone, a signal the trial could not confirm
What was tested
After curative chemoradiation: tiragolumab plus atezolizumab, atezolizumab alone, or placebo. For squamous esophageal cancer that could not be removed by surgery.
What they found
- The two-drug combination did not significantly delay the cancer's return: 20.8 vs 16.6 months (hazard ratio 0.82).
- Survival with the combination was similar to placebo: 38.6 vs 36.4 months.
- Atezolizumab alone showed better survival than placebo (hazard ratio 0.69), but the trial's design did not allow this to be formally tested.
- Side effects from treatment: 75% with the combination, 65% with atezolizumab alone, 55% with placebo.
What it means
The planned comparison failed. The atezolizumab-alone signal is the main reason the idea is not fully closed.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.